- Imeik Technology reported a net income of 963.4 million yuan in the first half of the year.
- This is a 65% increase compared to the same period last year, when the net income was 585.1 million yuan.
- Revenue also increased by 65% year-on-year, reaching 1.46 billion yuan.
- Market response has been positive, with 39 buys, and no holds or sells reported.
- The comparisons to past results are based on values reported by the company in its original disclosures.
A look at Imeik Technology Development C Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Imeik Technology Development Co., Ltd. is a biomedical products manufacturer and distributor with a broad range of products, including sodium hyaluronate, collagens, and polylactic acids. The company has recently been given a Smartkarma Smart Score of 1-5, indicating its outlook over the long-term.
The company scored highly in terms of growth and resilience, with a 5/5 rating for both. However, its scores for value and dividend were slightly lower at 2/5 each. Momentum also scored 2/5. Despite the lower scores for value and dividend, Imeik Technology Development Co., Ltd. is well-positioned for long-term success, with high ratings for growth and resilience.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
